Please login to the form below

Not currently logged in


This page shows the latest Regeneron news and features for those working in and with pharma, biotech and healthcare.

Segmentation, evolved

Segmentation, evolved

Sanofi and its partner Regeneron have evolved away from segmenting prescribers alone. ... These evolutionary adaptations are a response to market selection pressures. In the case of Sanofi/Regeneron, it’s a response to failing to achieve the

Latest news

More from news
Approximately 45 fully matching, plus 120 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market ... Regeneron remains the leading

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

  • Deal Watch September 2016 Deal Watch September 2016

    4, 325. Regeneron / Teva. Licence. Fasinumab in P3 for osteoarthritis pain, upfront payment $250m [excludes rights to Japan, Korea and other Asian markets].

  • Deal Watch April 2016 Deal Watch April 2016

    with deals by Regeneron, Madrigal and Tobira). ... 265 . Intellia (US). Regeneron (US). Co-development &co-commercialisation. Discovery stage CRISPR/Cas platform for treatments of liver disease.

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration &licence. $134. Regeneron/ Bayer. Ophthalmology combination therapy: nesvacumab (Ang2 antibody) and aflibercept (VEGF trap).

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

  • Tiziana Life Sciences appoints clinical sciences VP Tiziana Life Sciences appoints clinical sciences VP

    Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson &Johnson and Regeneron.

  • Regeneron taps Pfizer for CFO Regeneron taps Pfizer for CFO

    Landry assumes the role of senior VP at Regeneron immediately and will succeed Murray Goldberg as chief financial officer on October 1 when Goldberg steps after 18 years with Regeneron. ... We are extremely fortunate that Murray will stay at Regeneron

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...